

References

I-53

1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Bethesda, MD. Update 2020.
2. Maurer, M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med.* 2013;368(10):924-935.
3. Kelmenson D, Kelly V, Winkler T, et al. The effect of omalizumab on ventilation and perfusion in adults with allergic asthma. *Am J Nucl Med Mol Imaging.* 2013;3(4):350–360.
4. Saini S, Bindslev-Jensen C, Maurer M. et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. *J Invest Dermatol.* 2015;135(1):67-75.
5. Chen H, Huang C, Chang E, Kuo H. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. *BMC Pulm Med.* 2016;8;16(1):3.
6. Matin N, Tabatabaie O, Falsaperla F, et al. Efficacy and safety of omalizumab in paediatric age: An update of literature data. *J Biol Reg Homeo Agents.*2016;579-584.
7. Labrador-Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticarial. *Drug Design, Develop and Ther.* 2015;4909-4915.
8. Urgert MC, van den Elzen, Knulst AC, et al. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. *Brit Journ Derm.* 2015;404-415.
9. Lin CH, Cheng SL. A review of omalizumab for the management of severe asthma. *Drug Design, Development and Therapy.* 2016;2369-2378.
10. Munoz JP, Casado AF, Taboada AC, et al. Successful treatment of refractory idiopathic angiooedema with omalizumab: review of the literature and function of IgE in angio-oedema. *Clinical and Experimental Dermatology.* 2016;399–402.
11. Micromedex DrugDex Compendium®. 2023. Omalizumab.
12. Clinical Pharmacology Compendia™. 2023. Tampa FL: Gold Standard, Inc. Omalizumab.
13. Bhutani M, Yang W, Hebert J, et al. The Real World Effect of Omalizumab Add on Therapy for Patients with Moderate to Severe Allergic Asthma: The ASTERIX Observational Study. *Plos One.* 2017;12(8):1-13.

14. Beck L, Bernstein J, & Maurer M. A Review of International Recommendations for the Diagnosis and Management of Chronic Urticaria. *Acta Derm Venereol.* 2017;97:149-158.
15. Xolair® (omalizumab), injection, for subcutaneous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 02/2024.
16. Gevaert P, Omachi T, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. *J Allergy Clin Immunol.* 2020;146(3):595-605.
17. Omalizumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 1, 2016.